Get the Stockscreener App
16.84
4.91%
-0.87
Pre-market:
16.71
-0.13
-0.77%
Anaptysbio Inc Stock (ANAB) Latest News
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 - MarketBeat
Rhumbline Advisers Grows Position in AnaptysBio, Inc. (NASDAQ:ANAB) - Defense World
HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
When (ANAB) Moves Investors should Listen - Stock Traders Daily
Y Intercept Hong Kong Ltd Purchases Shares of 23,497 AnaptysBio, Inc. (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Leerink Partnrs Weighs in on AnaptysBio FY2029 Earnings - MarketBeat
AnaptysBio (ANAB) to Release Quarterly Earnings on Monday - MarketBeat
AnaptysBio: A Shadow Of Its Former Self (NASDAQ:ANAB) - Seeking Alpha
Palmoplantar Pustulosis Clinical and Non-Clinical Studies, - openPR
AnaptysBio’s (ANAB) Neutral Rating Reaffirmed at HC Wainwright - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Update - MarketBeat
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Strong Earnings - MarketBeat
H.C. Wainwright maintains AnaptysBio stock Neutral with $22 target By Investing.com - Investing.com Canada
Where AnaptysBio Stands With Analysts - Benzinga
AnaptysBio (ANAB) Expected to Announce Earnings on Monday - Defense World
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates - MSN
AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
AnaptysBio, Inc. (NASDAQ:ANAB) Sees Large Growth in Short Interest - Defense World
AnaptysBio (NASDAQ:ANAB) Issues Earnings Results - MarketBeat
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20 - MarketBeat
AnaptysBio Reports Strong Progress in Clinical Trials - TipRanks
AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst - TipRanks
AnaptysBio reports Q4 EPS (72c), consensus ($1.70) - TipRanks
AnaptysBio, Inc. (ANAB) Tops Q4 EPS by 90c - StreetInsider.com
ANAPTYSBIO, INC SEC 10-K Report - TradingView
Anaptys Announces Participation in March Investor Conferences - The Manila Times
AnaptysBio's Rosnilimab Achieves Highest-Ever RA Treatment Response RateWhat Does This Mean for Investors? - StockTitan
(ANAB) Investment Analysis - Stock Traders Daily
AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.7%Here's What Happened - MarketBeat
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 8.6% in January - Defense World
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? - MSN
What is HC Wainwright’s Forecast for AnaptysBio Q1 Earnings? - Armenian Reporter
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $51.00 - MarketBeat
AnaptysBio (NASDAQ:ANAB) Trading Up 16.5% After Analyst Upgrade - MarketBeat
Q1 Earnings Estimate for AnaptysBio Issued By HC Wainwright - Defense World
Wedbush Reaffirms Outperform Rating for AnaptysBio (NASDAQ:ANAB) - MarketBeat
AnaptysBio (NASDAQ:ANAB) Given New $51.00 Price Target at Wells Fargo & Company - Armenian Reporter
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):